• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review.卡介苗膀胱灌注与丝裂霉素C治疗Ta和T1期膀胱癌：Cochrane系统评价节略概述
Investig Clin Urol. 2020 Jul;61(4):349-354. doi: 10.4111/icu.2020.61.4.349. Epub 2020 Jun 29.
2
Re: Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.回复：一项关于浅表性膀胱癌患者丝裂霉素C和卡介苗序贯膀胱内治疗与单纯丝裂霉素C随机III期试验的结果
J Urol. 1999 May;161(5):1582-3. doi: 10.1016/s0022-5347(05)68976-8.
3
Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.卡介苗膀胱灌注在降低高危浅表性膀胱癌肿瘤复发方面优于丝裂霉素C：一项随机试验的荟萃分析
BJU Int. 2004 Mar;93(4):485-90. doi: 10.1111/j.1464-410x.2003.04655.x.
4
Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.回复：威廉·奥斯特林克、齐亚·基尔卡利、理查德·西尔维斯特等。膀胱原位癌患者序贯膀胱内丝裂霉素C与卡介苗化疗免疫疗法及单纯卡介苗化疗免疫疗法：欧洲癌症研究与治疗组织泌尿生殖组随机2期试验（30993）结果。《欧洲泌尿外科杂志》2011年；59卷：438 - 46页
Eur Urol. 2011 Jul;60(1):e1; author reply e2-3. doi: 10.1016/j.eururo.2011.03.050. Epub 2011 Apr 5.
5
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.卡介苗膀胱灌注与表柔比星治疗Ta和T1期膀胱癌的比较
Cochrane Database Syst Rev. 2011 May 11(5):CD006885. doi: 10.1002/14651858.CD006885.pub2.
6
Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?对于中危膀胱癌，膀胱内灌注卡介苗比丝裂霉素更好吗？
Eur Urol. 2009 Aug;56(2):257-8; discussion 258-9. doi: 10.1016/j.eururo.2009.04.041. Epub 2009 May 3.
7
Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.回复：佩尔-乌诺·马尔姆斯特伦、理查德·J·西尔维斯特、大卫·E·克劳福德等。一项个体患者数据荟萃分析，比较膀胱内注射丝裂霉素C与卡介苗治疗非肌层浸润性膀胱癌的随机研究的长期结果。《欧洲泌尿外科杂志》2009年；56卷：247 - 256页。
Eur Urol. 2010 Feb;57(2):e7-9; author reply e10-1. doi: 10.1016/j.eururo.2009.10.033. Epub 2009 Nov 10.
8
Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.一项针对浅表性膀胱癌患者的随机III期试验结果：丝裂霉素C与卡介苗序贯膀胱内治疗对比单纯丝裂霉素C治疗。
J Urol. 1998 Nov;160(5):1668-71; discussion 1671-2.
9
A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma.一项比较丝裂霉素C和卡介苗长期膀胱内灌注治疗浅表性膀胱癌患者的随机前瞻性研究。
J Urol. 1996 Aug;156(2 Pt 1):372-6. doi: 10.1016/s0022-5347(01)65853-1.
10
Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.每周使用丝裂霉素C，随后每月使用卡介苗，或每月交替使用α-干扰素2B和卡介苗，用于预防复发性乳头状浅表性膀胱癌。
J Urol. 2000 Jul;164(1):47-52.

引用本文的文献

1
A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy.一种分子标记物可确定对卡介苗膀胱内灌注治疗有反应的非肌肉浸润性膀胱癌的预后和治疗亚型。
Int J Mol Sci. 2021 Feb 1;22(3):1450. doi: 10.3390/ijms22031450.

本文引用的文献

1
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.卡介苗免疫疗法与丝裂霉素C化疗预防浅表性膀胱移行细胞癌的随机组间比较：西南肿瘤学组研究
Urol Oncol. 1995 May-Jun;1(3):119-26. doi: 10.1016/1078-1439(95)00041-f.
2
Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses.膀胱内治疗浅表性膀胱癌：随机试验和荟萃分析的系统评价。
Cancer Treat Rev. 2010 May;36(3):195-205. doi: 10.1016/j.ctrv.2009.12.005. Epub 2010 Jan 15.
3
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.卡介苗维持疗法与丝裂霉素C维持膀胱灌注疗法对无原位癌的频繁复发TaT1肿瘤的长期疗效：一项随访20年的前瞻性随机FinnBladder I研究的亚组分析
Eur Urol. 2009 Aug;56(2):260-5. doi: 10.1016/j.eururo.2009.04.009. Epub 2009 Apr 16.
4
A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.一项针对复发中危非肌层浸润性膀胱癌膀胱内预防治疗的随机前瞻性研究：丝裂霉素化疗与卡介苗免疫治疗对比
Arch Ital Urol Androl. 2008 Dec;80(4):167-71.
5
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.一项多中心随机前瞻性试验，比较三种用于中危浅表性膀胱癌的膀胱内辅助治疗方法：低剂量卡介苗（27毫克）对比极低剂量卡介苗（13.5毫克）对比丝裂霉素C。
Eur Urol. 2007 Nov;52(5):1398-406. doi: 10.1016/j.eururo.2007.04.062. Epub 2007 Apr 27.
6
Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.与短期膀胱内化疗以及非肌层浸润性膀胱癌患者的短期卡介苗（BCG）治疗相比，长期膀胱内辅助化疗可进一步降低复发率。
Eur Urol. 2007 Oct;52(4):1123-29. doi: 10.1016/j.eururo.2007.02.063. Epub 2007 Mar 12.
7
Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.一项比较丝裂霉素-C与卡介苗治疗高危膀胱癌患者的随机前瞻性研究10年后的进展和生存分析。
BJU Int. 2007 Apr;99(4):817-20. doi: 10.1111/j.1464-410X.2006.06706.x. Epub 2007 Jan 22.
8
Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.卡介苗膀胱灌注与丝裂霉素C治疗Ta和T1期膀胱癌的比较
Cochrane Database Syst Rev. 2003(3):CD003231. doi: 10.1002/14651858.CD003231.
9
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.膀胱内电动丝裂霉素C与被动转运丝裂霉素C治疗高危浅表性膀胱癌的前瞻性随机研究。
J Urol. 2003 Sep;170(3):777-82. doi: 10.1097/01.ju.0000080568.91703.18.
10
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.卡介苗膀胱灌注与丝裂霉素C治疗浅表性膀胱癌的比较：复发和毒性比较研究的正式荟萃分析
J Urol. 2003 Jan;169(1):90-5. doi: 10.1016/S0022-5347(05)64043-8.

Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review.

作者信息

Schmidt Stefanie, Kunath Frank, Coles Bernadette, Draeger Desiree Louise, Krabbe Laura-Maria, Dersch Rick, Kilian Samuel, Jensen Katrin, Dahm Philipp, Meerpohl Joerg J

机构信息

UroEvidence@Deutsche Gesellschaft für Urologie, Berlin, Germany.

Department of Urology, University Hospital Erlangen, Erlangen, Germany.

出版信息

Investig Clin Urol. 2020 Jul;61(4):349-354. doi: 10.4111/icu.2020.61.4.349. Epub 2020 Jun 29.

DOI:10.4111/icu.2020.61.4.349
PMID:32665991
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7329645/
Abstract
摘要